DUPIXENT® - Efficacy outcomes assessed in adult patients with moderate-to-severe AD

The SOLO 1, SOLO 2, and CHRONOS clinical trials1

Primary endpoint across all 3 pivotal trials:1

• Change from baseline to Week 16 in the proportion of subjects with an IGA 0 (clear) or 1 (almost clear) and at least 2-point improvement

Other endpoints:1

• Proportion of subjects with EASI-75 (improvement of at least 75% in EASI score from baseline)
• Reduction in itch as defined by at least a 4-point improvement in the peak pruritus NRS from baseline to Week 16
• Change from baseline to Week 52 in the proportion of subjects with an IGA 0 (clear) or 1 (almost clear) and at least 2-point improvement

Other patient-reported outcomes:1

• ≥4 points improvement in POEM
• ≥4 points improvement in DLQI

IGA: Investigator’s Global Assessment; EASI: Eczema Area and Severity Index; NRS: Numerical Rating Scale; POEM: Patient Oriented Eczema Measure; DLQI: Dermatology Life Quality Index
† Corresponding to minimal clinically important difference.


Dosing and Administration

Thinking about prescribing DUPIXENT®? Find helpful information to get started.
 

Freedom Support Program logo

Freedom Support Program

Find out what the Freedom Support Program can bring to your patients and how you can help them access it.



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300298
Last updated: 06/2023

paab logo